Flamel, part of Avadel Pharmaceuticals, is looking for subjects to participate in their clinical trial evaluating their once nightly sodium oxybate for the treatment of Excessive Daytime Sleepiness (EDS) and cataplexy in narcolepsy.

FT218 is dosed only once at bedtime, unlike the currently marketed formulation of sodium oxybate, which needs to be taken twice nightly – once at bedtime and then again 2.5-4 hours later.

Patients with a diagnosis of narcolepsy who meet the study criteria may be eligible to participate in our clinical trial.

• The study is currently open and recruiting patients in the USA, Canada, UK, Germany, France, Czech Republic, and Finland.
• Countries due to open in the coming month include Denmark, the Netherlands, and Switzerland.

Learn more about the FT218 REST-ON Clinical Trial at http://clinicaltrial.avadel.com